Sanofi bumps up full-year forecast after strong Q2 profit
July 25 (Reuters) -Sanofi's SASY.PA second-quarter profit rose 3.2% on strong demand for its blockbuster asthma drug Dupixent and better-than-expected sales of new launches, with the company now expecting a stable full-year profit compared to a prior forecast of a fall.
Operating income, excluding one-off items, rose 3.2% to 2.81 billion euros ($3.05 billion), above the 2.08 billion euros expected on average by analysts in a poll on the company's website.
The company now forecasts stable earnings per share 2024 business, from its previous forecast of a low single-digit percentage fall.
Sales of Dupixent, which is approved to treat conditions such as asthma and eczema, rose 29.2% to 3.30 billion euros, above analyst consensus estimates of 3.18 billion euros.
Anti-inflammatory drug Dupixent, on which Sanofi partners with Regeneron REGN.O, has long been a key growth driver, and the company has been seeking to expand its use for other conditions.
Still, Sanofi has faced shareholder concerns that it is overly reliant on Dupixent.
The French drugmaker has ramped up spending on research and development to revive its portfolio of experimental drugs and vaccines. It unexpectedly abandoned its 2025 margin targets in October for the R&D push, sparking a selloff in its stock.
Sanfoi's new launches include haemophilia treatment Altuviiio, Beyfortus to prevent a common respiratory infection in infants, and type 1 diabetes treatment Tzield.
Quarterly sales of Beyfortus, which it sells with AstraZeneca AZN.L, came in at 18 million euros, versus expectations of 15 million euros.
Sales of Altuviiio came in at 158 million euros, above estimates of 139 million.
Investors have been closely watching the performance of the new launches to gauge their near-term earnings potential.
($1 = 0.9226 euros)
Reporting by Manas Mishra in Bengaluru; Editing by Janane Venkatraman
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
